Akers Biosciences Inc (MYMD)

NASDAQ
3.79
+0.03(+0.80%)
  • Volume:
    42,533
  • Bid/Ask:
    3.77/3.79
  • Day's Range:
    3.62 - 3.79

MYMD Overview

Prev. Close
3.76
Day's Range
3.62 - 3.79
Revenue
360K
Open
3.74
52 wk Range
3.3 - 13.94
EPS
-3.17
Volume
42,533
Market Cap
139.81M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
560,349
P/E Ratio
-
Beta
0.22
1-Year Change
-48.21%
Shares Outstanding
37,282,169
Next Earnings Date
May 17, 2021
What is your sentiment on Akers Biosciences Inc?
or
Vote to see community's results!

Akers Biosciences Inc News

Akers Biosciences Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralSellStrong SellSell
Technical IndicatorsStrong BuyBuyStrong SellStrong SellSell
SummaryBuyNeutralStrong SellStrong SellSell

Akers Biosciences Inc Company Profile

Akers Biosciences Inc Company Profile

Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company’s product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin and for on- and off-the-job alcohol safety initiatives. The Company's primary focus is on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.

Read More
  • Merger
    0
    • https://www.businesswire.com/news/home/20201202005600/en/Akers%E2%80%99-Proposed-Merger-Partner-MyMD-Pharmaceuticals-Announces-Issuance-of-Key-Patent
      0
      • This stock needs more volume that's all.
        0
        • This stock needs more volume that's all.
          0
          • Any news?
            0
            • yok,ibneler share sayisini kisitlamislar
              0
          • pre market..
            0
            • +612%...
              0
              • what a day! still holding my bag until .60+
                0
                • looks like you lost your bag
                  0
                • In which Platform you are trade this one. I can't found it on MT5
                  0
              • the next is 0.60
                0
                • reverse splitting is a new method by which Americans steal money from investors
                  0
                  • reading more and more news about this stock on different forums lately- looks promising. Bought 500 shares at .42. Let see what this new CEO can do!
                    0
                    • hope this stock recovery
                      0
                      • When are we going to find out they got approve by fda or not ? What is the date
                        0
                        • AKER is sitting at a soft support. Possibly a good buy now.
                          0
                          • AKER is growing slow just how it is meant to... The higher ups don't want a bunch of shorts destroying the price. 3.50 by the end of next quarter.... Then 8.00 by the end of year.
                            1
                            • slow? u mean 500% in 3 months slow?
                              0
                            • How u know it will become 8?
                              0
                          • 6 days b4 earnings
                            0
                            • Going to run all, buy before financials come out.
                              0
                              • AKER seems like a massive EXODUS, who is for the long ride?
                                1
                                • me though i did cashed out for 1/4 at x5
                                  0
                                • I am as well.... At least until $1 - $1.2 then I'm out. I think this company has a great future but I don't have the funds yet to let my shares just sit there for a few years. The RSI, MACD and Ichimoku look good so I think we are good.
                                  0
                              • Did they get approval?
                                0
                                • I heard around STwits that they may be holding on to the FDA approval and will release it at or around the ER Wednesday. Not confirmed though.
                                  0
                              • at what point sell?
                                0
                                • Never.....
                                  0
                                • Andrew White  not taking profit at x5 is foolish in stock market
                                  0
                                • The strength and momentum look good for now. The consensus seems to be to either hold for years or to sell around $1.00 I am going to sell at $1 because I am playing with a small amount of money and don't want to let it sit in one stock for a few years. Good luck to ya!
                                  0
                              • Where can i find pending FDA info?
                                0
                                • Google FDA 501k then in the search tab type AKER
                                  0
                                • Thank you Jose, I have the same question but have never ask
                                  0
                                • What did u guys find from FDA? I dont understand any of that info.
                                  0
                              • Is it too late to get in now?
                                0
                                • Not necessarily. To the contrary of earlier sentiment, the share value decrease from a high in intraday trading recovered and consolidated, closing at a high from opening. Continuing the trend in previous days, with record volume levels on opening and closing bells, positive % in pre-market and after hours, and closing at highs over opening bell, AKER continues to gain momentum. Projections for Monday include positive gaps in share value, strong opening and high share value on closing, with increasing potential to surpass strong resistance at $1.00 by mid-week.
                                  0
                                • wait for dip at least
                                  0
                                • I love seeing people write honest and through responses! I always try to do the same. I was going to get out around $1.00 but we will see how it goes!
                                  0
                              • Will it behave like Juno therapy?
                                0
                                • guys it’s flying..:)
                                  0
                                  • Don't let this one slip past you. You stand to profit big when FDA approval is announced on the 5th - Expected PR release on February 5th, however the date might be delayed until March 5th. Hold your shares. This is worth holding. AKER is introducing a new STD test kit that will have a huge positive impact on the industry. Share value will easily quadruple, and there is a high probability of profit upwards of $2.75 per share, at a buy in of $0.25. Stack it deep! Stay long. Don't short. Wait for the target price of at least $2 before you begin to sell. This FDA deal is going to pay out big. Cheers! And you're welcome for the valuation and heads up.
                                    0
                                    • Additionally, I should note that this is a bull market, and the share value could quickly rise to $4-5. So keep that in mind if you think of shorting this event. Good luck everyone!
                                      0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.